Sign In
Buy 0HOY
Boston Scientific Earnings Calls
| Release date | Oct 22, 2025 |
| EPS estimate | $0.714 |
| EPS actual | $0.750 |
| EPS Surprise | 5.04% |
| Revenue estimate | 5.278B |
| Revenue actual | 5.065B |
| Revenue Surprise | -4.03% |
| Release date | Jul 23, 2025 |
| EPS estimate | $0.725 |
| EPS actual | $0.531 |
| EPS Surprise | -26.76% |
| Revenue estimate | 4.963B |
| Revenue actual | 5.061B |
| Revenue Surprise | 1.98% |
| Release date | Apr 23, 2025 |
| EPS estimate | $0.673 |
| EPS actual | $0.451 |
| EPS Surprise | -32.93% |
| Revenue estimate | 4.789B |
| Revenue actual | 4.663B |
| Revenue Surprise | -2.64% |
| Release date | Feb 05, 2025 |
| EPS estimate | $0.657 |
| EPS actual | $0.380 |
| EPS Surprise | -42.19% |
| Revenue estimate | 4.421B |
| Revenue actual | 4.561B |
| Revenue Surprise | 3.16% |
Last 4 Quarters for Boston Scientific
Below you can see how 0HOY.L performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 05, 2025 |
| Price on release | $105.65 |
| EPS estimate | $0.657 |
| EPS actual | $0.380 |
| EPS surprise | -42.19% |
| Date | Price |
|---|---|
| Jan 30, 2025 | $103.90 |
| Jan 31, 2025 | $103.33 |
| Feb 03, 2025 | $103.22 |
| Feb 04, 2025 | $103.11 |
| Feb 05, 2025 | $105.65 |
| Feb 06, 2025 | $105.26 |
| Feb 07, 2025 | $105.49 |
| Feb 10, 2025 | $106.06 |
| Feb 11, 2025 | $105.83 |
| 4 days before | 1.68% |
| 4 days after | 0.170% |
| On release day | -0.374% |
| Change in period | 1.86% |
| Release date | Apr 23, 2025 |
| Price on release | $99.40 |
| EPS estimate | $0.673 |
| EPS actual | $0.451 |
| EPS surprise | -32.93% |
| Date | Price |
|---|---|
| Apr 15, 2025 | $94.03 |
| Apr 16, 2025 | $95.20 |
| Apr 17, 2025 | $95.78 |
| Apr 22, 2025 | $94.81 |
| Apr 23, 2025 | $99.40 |
| Apr 24, 2025 | $100.98 |
| Apr 25, 2025 | $101.96 |
| Apr 28, 2025 | $102.10 |
| Apr 29, 2025 | $103.02 |
| 4 days before | 5.71% |
| 4 days after | 3.64% |
| On release day | 1.59% |
| Change in period | 9.56% |
| Release date | Jul 23, 2025 |
| Price on release | $107.00 |
| EPS estimate | $0.725 |
| EPS actual | $0.531 |
| EPS surprise | -26.76% |
| Date | Price |
|---|---|
| Jul 17, 2025 | $103.74 |
| Jul 18, 2025 | $102.35 |
| Jul 21, 2025 | $104.68 |
| Jul 22, 2025 | $103.85 |
| Jul 23, 2025 | $107.00 |
| Jul 24, 2025 | $105.11 |
| Jul 25, 2025 | $106.43 |
| Jul 28, 2025 | $106.46 |
| Jul 29, 2025 | $107.04 |
| 4 days before | 3.15% |
| 4 days after | 0.0326% |
| On release day | -1.77% |
| Change in period | 3.18% |
| Release date | Oct 22, 2025 |
| Price on release | $104.21 |
| EPS estimate | $0.714 |
| EPS actual | $0.750 |
| EPS surprise | 5.04% |
| Date | Price |
|---|---|
| Oct 16, 2025 | $97.75 |
| Oct 17, 2025 | $98.97 |
| Oct 20, 2025 | $100.78 |
| Oct 21, 2025 | $100.01 |
| Oct 22, 2025 | $104.21 |
| Oct 23, 2025 | $103.26 |
| Oct 24, 2025 | $101.66 |
| Oct 27, 2025 | $101.20 |
| Oct 28, 2025 | $101.22 |
| 4 days before | 6.61% |
| 4 days after | -2.87% |
| On release day | -0.91% |
| Change in period | 3.55% |
Boston Scientific Earnings Call Transcript Summary of Q3 2025
Boston Scientific reported a very strong Q3 2025: operational sales grew 19% and organic sales grew 15%, exceeding guidance. Adjusted EPS was $0.75 (up 19%), and the company raised full-year organic revenue guidance to ~15.5% and adjusted EPS to $3.02–$3.04. Regionally, the U.S. was especially strong (+27% operational), Asia Pacific grew mid-teens (including WATCHMAN FLX Pro approval in China), while EMEA was pressured by (1) the May discontinuation of the ACURATE valve (~$50M prior-year sales) and (2) an ERP implementation-related ~ $30M backorder in Kerkrade expected to normalize through Q4. Key growth drivers: electrophysiology (EP) — FARAPULSE and mapping ecosystem (EP grew 63%); WATCHMAN — grew 35% with accelerating concomitant procedures and strong penetration; continued strength in cardiology (AGENT DCB), venous (Varithena/EKOS), Interventional Oncology, Endoscopy, and Neuromodulation (including the announced agreement to acquire Nalu Medical). Financials: adjusted gross margin improved (71% in Q3), adjusted operating margin expanded to 28%, Q3 free cash flow was $1.163B and full-year FCF guidance is ~$3.5B. Tariffs (~$100M headwind for the year) remain a factor but company expects slight full-year gross margin improvement and ~100 bps operating margin expansion for 2025. Capital allocation priority is tuck-in M&A (recent Elutia asset close; Nalu acquisition expected H1 2026) followed by buybacks. Long-range targets (2026–2028) reaffirmed: 10%+ average organic revenue growth, ~50 bps annual operating margin expansion, double-digit EPS growth, and 70–80% free cash flow conversion. Risks called out include the ERP-related backorder, tariffs, and regulatory/clinical trial outcomes (e.g., CHAMPION).
